Welcome to our dedicated page for TriSalus Life Sciences SEC filings (Ticker: TLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TriSalus Life Sciences, Inc. (Nasdaq: TLSI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. TriSalus identifies itself in these filings as an emerging growth company and an oncology-focused medical technology business built around its Pressure-Enabled Drug Delivery (PEDD) platform and investigational immunotherapy, nelitolimod.
Through Forms 8-K, TriSalus reports material events such as quarterly financial results, business updates, changes in directors, compensation decisions and capital structure actions. Recent 8-K filings describe press releases announcing results for quarters ended June 30 and September 30, 2025, along with revenue performance driven by sales of the TriNav system. Other 8-Ks detail an exchange offer and consent solicitation related to Series A Convertible Preferred Stock, amendments to the certificate of designations, and subsequent conversion of preferred shares into common stock.
These filings also document governance and compensation matters, including director resignations and adjustments to executive base salary and performance-based stock option grants that vest upon achieving specified revenue thresholds. Together, they provide insight into how TriSalus manages its capital structure, aligns management incentives and responds to financing needs while advancing its PEDD-based devices and clinical-stage immunotherapy.
On Stock Titan, SEC documents for TLSI are updated as they are made available through EDGAR. AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, operating results, capital structure changes and governance items, and make it easier to interpret the implications of each report. This allows users to quickly understand what TriSalus is disclosing about its operations, financial condition and strategic decisions without reading every page in detail.
TriSalus Life Sciences reported strong growth for 2025 but remained unprofitable. Revenue from the TriNav system reached $45.2 million for the year, up 53% from 2024, with fourth quarter revenue of $13.2 million, a 60% year-over-year increase and 14% sequential growth.
Full-year gross profit rose to $38.2 million, though gross margin edged down to 84.6%, reflecting launch-related manufacturing inefficiencies. Operating loss narrowed to $26.9 million, and adjusted EBITDA loss improved to $17.2 million. Net loss attributable to common stockholders expanded to $69.7 million, mainly due to preferred stock conversion-related items.
Cash and cash equivalents were $20.4 million as of December 31, 2025, and subsequent to year-end the company raised $46 million in gross proceeds via a public offering. Management reaffirmed 2026 revenue guidance of $60–62 million and highlighted continued commercial adoption of TriNav, higher gross margins in Q4 2025, and ongoing investments in clinical studies and new PEDD-based products.
TriSalus Life Sciences is offering 9,756,100 shares of Common Stock at a public offering price of $4.10 per share, as set forth in the prospectus supplement dated February 19, 2026. The offering includes a 30-day underwriter option to purchase up to 1,463,415 additional shares.
The cover page shows aggregate public offering proceeds of $40,000,010, underwriting discounts of $2,400,000, and estimated proceeds to the company before expenses of $37,600,010. The prospectus supplement states estimated net proceeds of approximately $37.0 million (or approximately $42.64 million if the over-allotment is exercised in full) to be used for general corporate purposes.
TriSalus Life Sciences, Inc. Chief Financial Officer David Patience reported an open-market purchase of 3,657 shares of common stock at $4.10 per share. Following this transaction, his directly owned stake increased to 268,657 shares, signaling additional personal capital committed to the company.
TriSalus Life Sciences director Gary B. Gordon purchased 9,756 shares of the company’s common stock in an open-market transaction at $4.10 per share on February 23, 2026. Following this purchase, he directly owns 9,756 common shares of TriSalus Life Sciences, Inc.
TriSalus Life Sciences director William Valle reported an open-market purchase of company stock. On this Form 4, he bought 30,487 shares of TriSalus Life Sciences, Inc. common stock at a price of $4.10 per share. Following this transaction, he directly owns 30,487 common shares.
TriSalus Life Sciences CEO Mary T. Szela reported an open-market purchase of 30,487 shares of common stock at $4.10 per share. After this buy, she directly owns 773,289 shares, increasing her personal stake in the company.
TriSalus Life Sciences director Michael P. Stansky reported significant open-market purchases of the company’s common stock. He bought 243,900 shares directly at $4.10 per share and 117,198 shares at $4.10 per share through Skyview Investments LLC.
After these transactions, his direct holdings total 787,132 common shares, and his indirect holdings through Skyview Investments LLC total 199,698 common shares, reflecting continued equity ownership aligned with the company’s shareholders.
TriSalus Life Sciences filed a prospectus supplement to offer 9,756,100 shares of Common Stock at a public offering price of $4.10 per share, with a 30-day underwriter option for 1,463,415 additional shares. Net proceeds are estimated at approximately $37.0M (or $42.64M if the option is fully exercised) to be used for general corporate purposes.
The prospectus states pro forma shares outstanding of 59,811,590 after the offering (or 61,275,005 if the over-allotment is exercised). Preliminary unaudited results disclose $13.2M in fourth-quarter 2025 revenue, full-year 2025 revenue of $45.2M, and cash and cash equivalents of approximately $20.4M as of December 31, 2025.
TriSalus Life Sciences, Inc. has entered into an underwriting agreement for a public offering of 9,756,100 shares of its common stock at $4.10 per share. The company also granted underwriters a 30-day option to buy up to 1,463,415 additional shares to cover over-allotments.
Gross proceeds are expected to be about $40.0 million, with estimated net proceeds of approximately $37.0 million without exercising the option, or about $42.64 million if the option is fully exercised. TriSalus plans to use the cash for general corporate purposes, including capital spending, working capital, and administrative costs.
The deal is being made under an effective Form S-3 shelf registration, with Lake Street Capital Markets acting as sole book-runner. The offering is expected to close around February 23, 2026, and the company, its officers, directors, and a key securityholder have agreed to 90-day lock-up periods.
TriSalus Life Sciences, Inc. is offering shares of its common stock pursuant to a preliminary prospectus supplement dated February 19, 2026. The prospectus supplement supplements a shelf registration and describes the terms and mechanics of a primary offering of Common Stock listed on Nasdaq as "TLSI."
The filing discloses preliminary unaudited financial context: estimated Q4 2025 revenue of $13.2 million, full-year 2025 revenue of $45.2 million, and approximately $20.4 million of cash and cash equivalents as of December 31, 2025. The company states net proceeds will be used for general corporate purposes and that underwriting details, offering price and number of shares are set forth in the prospectus supplement (subject to completion).